AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 4:05 PM ET LB Pharmaceuticals reported a net loss of $59.1 million for the third quarter ended September 30, 2026, with cash of $403.8 million. AI-generated summary · Source: company release
$LBRXBiotechnologyClinical evidenceDevelopment risk

LBRX Stock Hub: LB Pharmaceuticals News, LB-102 and Schizophrenia

LB Pharmaceuticals’ November 5 Q3 results show a well-funded but increasingly expensive path to pivotal data. Cash, equivalents and short-term investments stood at $403.8 million at September 30 after the July $150 million private placement, while quarterly R&D rose to $51.5 million and GAAP net loss reached $59.1 million. Management still targets first-half 2027 topline results from the pivotal NOVA-2 schizophrenia trial, followed by a pre-NDA meeting in H2 2027, and guides runway beyond Q2 2029. Those are development and liquidity forecasts, not proof of approval or sustainable cash generation. Official Q3 results.

Last updated: November 9, 2026Market reference: November 6, 2026 regular-session closeFinancial period: September 30, 2026 Q3; June data historicCurrency: U.S. dollars unless stated
Full research report · PDF
LB Pharmaceuticals ($LBRX), research updated November 8, 2026
19 pages covering LB-102 pharmacology, the randomized NOVA-1 dose comparisons and the limits of exploratory cognition findings. It separates measured weight changes from adverse-event summaries and follows NOVA-2, long-term safety development, June liquidity, July financing, employee equity and dilution. The PDF is a dated edition; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next announced investor event
November 12, 2026 · 9:20 a.m. ET

Stifel fireside chat. The Guggenheim fireside chat was scheduled for November 9 at 1:00 p.m. ET.

NOVA-2 topline remains guided to H1 2027; the Stifel fireside chat is an investor event, not a clinical readout.
LB Pharmaceuticals LBRX daily stock chart
Daily chart $LBRX. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

LBRX stock at a glance

Close · November 6, 2026
$42.01
Regular session; +10.29% versus $38.09 on November 5.
Equity value · dated common shares
~$1,359.6M
Calculated from the November 6 close of $42.01 and 32.363 million common shares at November 3, 2026; pre-funded warrants excluded.
Cash + short-term investments
$403.760M
September 30, 2026; July placement proceeds included · Q3 results
Q3 GAAP net loss
−$59.066M
Three months to September 30; $1.79 loss/share · Q3 statement
Product revenue
None
Through September 30, 2026 (Q3) · investigational program
Q3 R&D expenditure
$51.516M
Versus $2.419M in year-earlier Q3; trial-driven and not a recurring monthly burn estimate · Q3 results
Common shares
32.363M
32,363,040 at November 3, 2026 · Q3 Form 10-Q cover
Funding runway · company estimate
Beyond Q2 2029
From September 30 balance, under planned operations; private placement already included · Q3 guidance

Where LB Pharmaceuticals stands now

LB Pharmaceuticals develops investigational LB-102, an oral D2/D3/5-HT7 antagonist. NOVA-1 reported randomized acute-schizophrenia efficacy at 50 and 75 mg; the smaller 100 mg comparison was nominal and does not remove dose-specific tolerability questions. The November 5 results keep pivotal NOVA-2 topline targeted for H1 2027, with a planned FDA pre-NDA meeting in H2 2027, while the 52-week open-label safety study NOVA-3 continues to enroll patients. Phase 2 ILLUMINATE-1 in bipolar-I depression is enrolling with results expected Q1 2028, and the adjunctive MDD Phase 2 study is planned for early 2027. Each program has separate proof, spending and timing requirements. November 5 corporate update.

Financial bridge and expense quality. September liquidity of $403.760 million includes the July $150 million private placement (approximately $140.9 million net), rather than representing product-generated cash. Q3 R&D was $51.516 million, up from $2.419 million a year earlier, and G&A was $10.982 million versus $2.827 million; operating loss was $62.498 million and GAAP net loss $59.066 million. The higher cost base reflects active Phase 3 and Phase 2 studies, hiring and public-company costs. Management guides resources beyond Q2 2029, but that is an operating-plan forecast. The October $200 million ATM registration remains an additional possible issuance route, not cash already raised. Q3 financial statements.

Pivotal confirmation and long-term tolerability remain pending. Exploratory cognition findings, preclinical experiments and pivotal trial-in-progress posters are different evidence classes. Weight changes and the smaller nominally tested dose arm constrain efficacy and tolerability conclusions.

The constructive case

Randomized Phase 2 efficacy and $403.8 million September liquidity support pivotal development into the announced 2027 data window. Replication, adequate long-term safety, and a usable label could strengthen the clinical case; they are not established outcomes.

The cautious case

Weight and prolactin findings matter. Cognition analyses remain exploratory. The $59.1 million Q3 GAAP loss, accelerated trial spending, ATM flexibility and warrant exposure constrain per-share value despite the runway, while approval would still leave a competitive launch challenge.

Latest LB Pharmaceuticals news

Nov 5, 2026

LB Pharmaceuticals reports third quarter 2026 financial results and provides corporate update

LB Pharmaceuticals reported a net loss of $59.1 million and research and development expenses of $51.5 million for the three months ended September 30, 2026. Cash, cash equivalents, and short-term investments were $403.8 million as of September 30, 2026, expected to support operations beyond the second quarter of 2029. Topline data from the Phase 3 NOVA-2 trial of LB-102 in schizophrenia is expected in the first half of 2027.

Oct 15, 2026

Investor conferences: Craig-Hallum, Guggenheim, Wolfe and Stifel

LB Pharmaceuticals said management will take part in the Craig-Hallum Biotech Catalyst Conference (virtual fireside chat on October 22, 2026 at 10:00 a.m. ET), the Guggenheim Securities Healthcare Innovation Conference in Boston (fireside chat on November 9 at 1:00 p.m. ET), the Wolfe Research Healthcare Conference in New York (one-on-one meetings on November 10) and the Stifel Healthcare Conference in New York (fireside chat on November 12 at 9:20 a.m. ET). Webcasts of the fireside chats will be posted on the Events page of the investor website. The announcement contains no new data. Source

Oct 10, 2026

ECNP posters

Four ECNP posters; only the highlighted microdialysis dataset is new preclinical evidence.

Oct 9, 2026

Executive incentives

Executive inducement options, not open-market purchases.

Oct 6, 2026

R&D Day announcement

The October 6 announcement scheduled the R&D Day for October 27. That event date is past and was not an announced Phase 3 topline date.

Aug 11, 2026

Quarterly finances and clinical progress reported

June cash and equivalents of $283.111 million plus marketable securities of $44.679 million totaled a calculated $327.790 million. The later July financing is excluded from that June balance.

LBRX stock catalysts: development and reporting dates

  • November 9, 2026 — Guggenheim fireside chat,1:00 p.m. ET. Scheduled event, November 9
  • November 12, 2026 — Stifel fireside chat,9:20 a.m. ET. Company schedule
  • First half of 2027 — NOVA-2 topline. Company target
  • Q1 2027 — Possible update on negative-symptom schizophrenia trial design. Company objective
  • H2 2027 — Planned pre-NDA FDA meeting after NOVA-2, subject to results. Not approval
  • Q1 2028 — ILLUMINATE-1 bipolar depression Phase 2 topline expected. Management target

Current investor-conference schedule · Quarterly financial statement

November 5 Q3 and pipeline timetable

LB-102 mechanism and NOVA-1 evidence

The original NOVA-1 randomized trial was published in JAMA Psychiatry on April 22, 2026, under DOI 10.1001/jamapsychiatry.2026.0428. It enrolled adults aged 18–55 with schizophrenia and an acute exacerbation requiring hospitalization. Eligibility included PANSS total scores of 80–120 and other symptom-severity requirements. This was a selected inpatient population, not an unselected outpatient sample with stable illness. A total of 359 participants were randomized to once-daily placebo or LB-102 at 50, 75, or 100 mg. The groups contained 108, 107, 108, and 36 participants, respectively. Treatment lasted 28 days, followed by stabilization and safety follow-up. The substantially smaller 100 mg cohort deserves explicit attention whenever its effect or adverse-event percentage is compared with the other arms.

LB Pharmaceuticals capital and pivotal development

At June 30, 2026, the unaudited balance sheet reported $283.111 million in cash and cash equivalents and $44.679 million in marketable securities. Together these equal a calculated $327.790 million, conventionally rounded to $327.8 million. Restricted cash of $0.782 million is a separate line and is not included in that liquidity total. The figures precede the July financing and several additional months of operating expenditure. Source: complete Q2 2026 Form 10-Q, balance sheets; combined liquidity is arithmetic.

Merlintrader Health Score · $LBRX

Reviewed November 6, 2026 after Q3. The original provisional scoring framework is retained; trading liquidity remains unscored.

Merlintrader Health Score · 3.06 / 5 · provisional

Editorial robustness assessment over 12–18 months, revisited November 6, 2026, and reviewed again November 9, 2026 with scores unchanged—not a valuation, clinical success probability, or recommendation. The five house pillars are balance sheet/runway 30%, catalysts 30%, dilution 20%, trading liquidity 10%, and execution 10%. Trading liquidity is unscored; a dated close does not measure spread or order-book depth; the provisional result covers 90% of the weights: (0.30 × 4 + 0.30 × 3 + 0.20 × 2 + 0.10 × 2.5) ÷ 0.90 = 3.06 / 5.

Component / weightScoreReason
Balance sheet / runway · 30%4 / 5September liquidity $403.8M includes the July private placement; rising trial R&D costs and funding runway beyond Q2 2029 remain forecast-dependent.[2]
Catalysts · 30%3 / 5Positive Phase 2; pivotal and long-term confirmation pending.[5]
Dilution · 20%2 / 5Warrants, options, and ATM capacity.[2][10]
Trading liquidity · 10%Not scoredNot included in the provisional score.
Execution · 10%2.5 / 5NOVA-2 remains on track for H1 2027 topline, but Q3 R&D $51.5M demonstrates execution cost; no completed pivotal result.[22][31]

These are disclosed editorial judgments, not measurements supplied by the company. The provisional score excludes trading liquidity.

Red flags

  • Exploratory cognition findings, preclinical experiments and pivotal trial-in-progress posters are different evidence classes. Weight changes and the smaller nominally tested dose arm constrain efficacy and tolerability conclusions.
  • Weight and prolactin findings matter. Cognition analyses remain exploratory. Financing flexibility and warrants create dilution exposure, while approval would still leave a competitive launch challenge.
  • Q3 R&D of $51.5M and net loss of $59.1M substantially exceed year-earlier levels as pivotal development accelerates.
  • September liquidity includes the July private placement; the October ATM is possible future dilution, not available operating cash.

LBRX Stock FAQ: LB Pharmaceuticals Questions Answered

What is the next catalyst for LBRX stock?

LB Pharmaceuticals’ next scheduled investor event is a Stifel fireside chat on November 12, 2026, at 9:20 a.m. Eastern, after a Guggenheim fireside chat scheduled for November 9 at 1 p.m. Eastern. The main clinical target is NOVA-2 schizophrenia topline data in the first half of 2027, according to its November 5, 2026 Q3 update (SEC Exhibit 99.1). Investor conference schedule. NOVA-2 development timeline.

Is LB Pharmaceuticals’ LB-102 FDA approved?

LB-102 remained investigational in LB Pharmaceuticals’ October 10, 2026 update, with NOVA-2 evaluating schizophrenia efficacy and NOVA-3 longer-term safety. Its November 5, 2026 Q3 update (SEC Exhibit 99.1) still expects to schedule a pre-NDA meeting with the FDA in the second half of 2027, after NOVA-2 data. A planned meeting is not an accepted application or marketing approval. October clinical-development update. Planned FDA meeting.

How much liquidity does LB Pharmaceuticals have after Q3 2026?

At September 30, 2026, LB Pharmaceuticals held $403.760 million in cash, equivalents and short-term investments. The figure incorporates the July $150 million private placement, which supplied approximately $140.9 million net; it must not be added to September liquidity again. Q3 R&D was $51.516 million, G&A $10.982 million and net loss $59.066 million, reflecting expanding clinical development. Management expects the financial resources to support planned operations beyond Q2 2029, but the timing depends on trial spending and financing assumptions. November 5 official results.

Could LB Pharmaceuticals issue more LBRX shares?

Yes. LB Pharmaceuticals reported 32,363,040 common shares outstanding on November 3, 2026, in its Q3 Form 10-Q, while July’s financing also included pre-funded warrants for 715,513 shares. Its October 1 registration included a separate $200 million ATM sales agreement with TD Securities. That authorization permits future issuance; it does not demonstrate that the full amount has been sold or received. Q3 Form 10-Q share count. July pre-funded warrants (June Form 10-Q). October registration, ATM prospectus.

What did LBRX report for the September 2026 quarter?

The company released Q3 2026 results on November 5: net loss of $59.066 million ($1.79/share), research and development expense of $51.516 million and general and administrative expense of $10.982 million, with $403.760 million in cash and short-term investments at September 30. It reiterated NOVA-2 pivotal schizophrenia topline in H1 2027. The GAAP loss is not an exact measure of cash consumed by operations, and financing is distinct from product revenue. No next quarterly reporting date is specified in this release. Company financial results.

What does LB Pharmaceuticals do?

LB Pharmaceuticals develops experimental medicines for brain disorders, according to its October 10, 2026 update. Lead candidate LB-102 is an oral antagonist of dopamine D2/D3 and serotonin 5-HT7 receptors, being studied in schizophrenia and mood disorders. Its pipeline includes pivotal schizophrenia development and the ILLUMINATE-1 bipolar-depression study; commercial approval remains pending. Company, mechanism and clinical pipeline.

Did LB Pharmaceuticals’ NOVA-1 confirm every dose and show no weight gain?

No. The 2026 NOVA-1 publication reports multiplicity-controlled primary comparisons for 50 and 75 mg; the 100 mg arm had only 36 randomized participants and nominal testing. Table 3 reports mean day-28 weight increases of 4.3, 3.3 and 2.9 kg at those doses, versus 2.0 kg with placebo. These measured weight changes differ from adverse-event reporting and require longer-term tolerability follow-up. NOVA-1 statistical methods and safety Table 3.

Did LB Pharmaceuticals release Phase 3 results at ECNP?

No. LB Pharmaceuticals’ October 10, 2026 ECNP announcement covered a new preclinical rat experiment, an encore cognition analysis and posters describing ongoing trials. Cognition was an exploratory NOVA-1 endpoint, with an additional post hoc analysis. The presentations did not report NOVA-2 or ILLUMINATE-1 topline results. ECNP poster content. NOVA-1 exploratory cognition endpoint.

Primary sources

This blog content is provided for informational and educational purposes only. It is not investment advice.

Disclaimer. Educational and informational content, not investment advice, a recommendation, or an offer to buy or sell securities. Clinical development, regulation, financing, dilution, and commercialization carry risks. Investors can lose some or all of their capital. Verify primary sources, conduct your own research, and consult a licensed adviser where appropriate.

Data are dated and may change. Interpretations and the Health Score are editorial, not clinical validation or forecasts. Some links, including Finviz, may generate affiliate commissions at no cost to readers. Full disclaimer · Terms and privacy.